Yuluka Health SAS is in the final completion stage of its licensing and infrastructure upgrades to its subsidiary, CBD Pharmaceuticals, in Colombia. The signing of multiple long-term supply contracts with European wholesalers will start this calendar year.
According to the terms of the agreements entered into on January 2022, CBD Pharmaceuticals will supply between 50 million to 100 million seeds from its library of strains to the European market and will continue to serve as a long-term provider for its partners. These agreements were executed by companies with extensive experience in the wholesale distribution of seeds to the retail and e-commerce market.
